| scholarly article | Q13442814 |
| P356 | DOI | 10.1592/PHCO.24.13.1110.38091 |
| P698 | PubMed publication ID | 15460171 |
| P2093 | author name string | Craig W Hendrix | |
| Mary Beth Wire | |||
| Yu Lou | |||
| George E Bigelow | |||
| Edward J Fuchs | |||
| Elizabeth Martinez | |||
| Jerry W Snidow | |||
| Jared Christopher | |||
| John Wakeford | |||
| P2860 | cites work | Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4 | Q24564971 |
| Decreased methadone effect after ritonavir initiation | Q28368991 | ||
| Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir | Q32067953 | ||
| Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males | Q33981408 | ||
| Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. | Q34543319 | ||
| Weak Binding of VX-478 to Human Plasma Proteins and Implications for Anti-Human Immunodeficiency Virus Therapy | Q38508315 | ||
| Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers | Q39473480 | ||
| The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine | Q44335550 | ||
| High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans | Q44338361 | ||
| Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans | Q44352672 | ||
| Lack of methadone dose alterations or withdrawal symptoms during therapy with lopinavir/ritonavir | Q44539534 | ||
| The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients | Q44540993 | ||
| The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone | Q44770188 | ||
| Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men. | Q44866694 | ||
| Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions | Q47900779 | ||
| Effects of buprenorphine and methadone in methadone-maintained subjects. | Q54493915 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| opioid | Q427523 | ||
| enantiomer | Q494483 | ||
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 1110-1121 | |
| P577 | publication date | 2004-09-01 | |
| P1433 | published in | Pharmacotherapy | Q7180800 |
| P1476 | title | Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects | |
| P478 | volume | 24 |
| Q27692040 | A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice |
| Q37000733 | Drug interactions in the management of HIV infection: an update |
| Q36399718 | Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug |
| Q36641870 | Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities |
| Q34633457 | Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir |
| Q91386089 | Methadone Metabolism and Drug-Drug Interactions: In Vitro and In Vivo Literature Review |
| Q37950478 | Methadone: a review of drug-drug and pathophysiological interactions |
| Q44346297 | Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone |
| Q42660244 | Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects |
| Q34487284 | Pharmacokinetics of methadone |
Search more.